BMRN · Biomarin Pharmaceutical Inc
United States · RS rating 33 · As of 2026-10-14
| Price | 55.14 USD |
|---|---|
| 1-day change | +1.4% |
| RS rating (overall / 1M / 3M / 12M) | 33 / 17 / 36 / 54 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 30 / 32 / 10 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -50.0% |
| Sales growth Q/Q | +12.7% |
| Distance from 52-week high | +21.5% |
| Market cap (USD) | $10.4B |